A study combined p16 and p53 expressions in CCUP revealed that patients with both p16‐negative and p53‐positive tumors showed a significantly poorer tumor‐specific survival (TSS) compared to those with either p16+/p53−, p16+/p53+, or p16−/p53−, which may represent as a method for risk stratification 16. The gene discussed is TP53; the disease is neoplasm.